132 related articles for article (PubMed ID: 35913013)
61. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
[TBL] [Abstract][Full Text] [Related]
62. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers.
Kleist B; Meurer T; Poetsch M
Tumour Biol; 2017 Mar; 39(3):1010428317692246. PubMed ID: 28345467
[TBL] [Abstract][Full Text] [Related]
63. Detection of
Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
[TBL] [Abstract][Full Text] [Related]
64. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
65. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
66. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
67. [Scanning for KRAS, NRAS, BRAF, and PIK3CA mutations by DNA melting analysis with TaqMan probes].
Botezatu IV; Panchuk IO; Stroganova AM; Senderovich AI; Kondratova VN; Shelepov VP; Lichtenstein AV
Mol Biol (Mosk); 2017; 51(1):50-58. PubMed ID: 28251966
[TBL] [Abstract][Full Text] [Related]
68. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
[TBL] [Abstract][Full Text] [Related]
69. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
[TBL] [Abstract][Full Text] [Related]
70. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
71. Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping.
Piton N; Lonchamp E; Nowak F; Sabourin JC;
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1416-8. PubMed ID: 26189770
[TBL] [Abstract][Full Text] [Related]
72. Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene.
Mariani S; Bertero L; Osella-Abate S; Di Bello C; Francia di Celle P; Coppola V; Sapino A; Cassoni P; Marchiò C
Br J Cancer; 2017 Jul; 117(3):358-366. PubMed ID: 28618430
[TBL] [Abstract][Full Text] [Related]
73. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
Lasota J; Kowalik A; Felisiak-Golabek A; Inaguma S; Wang ZF; Pięciak L; Zięba S; Pęksa R; Kopczynski J; Okoń K; Waloszczyk P; Gozdz S; Biernat W; Miettinen M
Arch Pathol Lab Med; 2017 Apr; 141(4):564-568. PubMed ID: 28353383
[TBL] [Abstract][Full Text] [Related]
74. Microsatellite Instability in Greek Colorectal Carcinoma Patients: Clinicopathological and Molecular Correlations.
Katafygiotis P; Sakellariou S; Chatziandreou I; Giannopoulou I; Thymara I; Saetta AA; Korkolopoulou P
Anticancer Res; 2019 Nov; 39(11):6379-6387. PubMed ID: 31704871
[TBL] [Abstract][Full Text] [Related]
75. Is there any correlation among MKK4
Dogan M; Guresci S; Acikgoz Y; Ergun Y; Kos FT; Bozdogan O; Bal O
Expert Rev Mol Diagn; 2020 Aug; 20(8):851-859. PubMed ID: 32552144
[TBL] [Abstract][Full Text] [Related]
76. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
77. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.
Cicenas J; Tamosaitis L; Kvederaviciute K; Tarvydas R; Staniute G; Kalyan K; Meskinyte-Kausiliene E; Stankevicius V; Valius M
Med Oncol; 2017 Feb; 34(2):26. PubMed ID: 28074351
[TBL] [Abstract][Full Text] [Related]
78. Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population.
Laskar RS; Talukdar FR; Choudhury JH; Singh SA; Kundu S; Dhar B; Mondal R; Ghosh SK
Tumour Biol; 2015 Jun; 36(6):4661-70. PubMed ID: 25647260
[TBL] [Abstract][Full Text] [Related]
79. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
[TBL] [Abstract][Full Text] [Related]
80. [Correlation Research between Syndrome Elements of Chinese Medicine and KRAS, BRAF, NRAS Gene Mutations in Advanced Colorectal Cancer Patients].
Xu ZN; Yang YF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Dec; 36(12):1445-1448. PubMed ID: 30650287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]